Core Insights - Nanobiotix presented new data from the third cohort of its Phase I 1100 study in melanoma at the Immunorad conference in Paris [2] Company Overview - The conference call was led by Joanne Choi, Head of U.S. Investor Relations, and included participation from Laurent Levy, Co-Founder and CEO [3] Research and Development - The call discussed forward-looking statements regarding the company's research and clinical development, highlighting the potential for significant risks and uncertainties that may affect actual results [3]